Jacobio, a China-based clinical-stage pharmaceutical company, announced on Sunday that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) in the United States for the company's self-developed global first-in-class drug Aurora A inhibitor JAB-2485.
The company is planning to start a Phase I/IIa clinical trial in patients with advanced solid tumours in the United States.
The product is a highly selective small molecule Aurora A inhibitor that can inhibit Aurora A activity at the cellular level, induce apoptosis and inhibit tumour growth. The inhibitory activity of Aurora A is one thousand times higher than that of Aurora B, and has potential to benefit patients with small cell lung cancer and triple negative breast cancer.
The company's self-developed JAB-2485 is the third Aurora A inhibitor enter into clinical stage in the United States.
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Rocket Pharmaceuticals secures FDA approval for Kresladi gene therapy in severe LAD-I
Pharming receives positive CHMP opinion for Joenja marketing authorisation
Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Lupin reports tentative FDA approval for Pitolisant Tablets
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics
Merck to acquire Terns Pharmaceuticals for USD6.7bn
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency